HCC CONNECT powered by COR2ED (@hccconnectinfo) / X

HCC CONNECT powered by COR2ED

1,044 posts

HCC CONNECT powered by COR2ED

@hccconnectinfo

COR2ED brings you Independent Medical Education developed by HCC CONNECT, international experts in Liver oncology. cor2ed.com/community-guid…

cor2ed.com/connects/hcc-c…

Joined March 2017

HCC CONNECT powered by COR2ED
@hccconnectinfo
Oct 7, 2025
Explore the expanding role of immunotherapy in HCC 📜 Tap image to see the flashcard! Find out more about combining locoregional & systemic treatments in intermediate hepatocellular carcinoma (HCC) --> From Prof. @RuthHe12 & Prof. @BeauToskichMD Endorsed by @dice_europe
59K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Aug 28, 2025
Treatment strategies for pts with advanced HCC who are ineligible for immunotherapy or with progression on IO >> See the flashcard! Click the image in this post to enlarge 📜 Supported by an Independent Educational Grant from Bayer
98K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Jun 22, 2023
🔥 Out now The 2nd learning module in a 2-part series on the use of #immunotherapy in #HCC. You'll learn about subgroup analyses and challenges of #IO for pts with HCC Check out module 1 if you haven't already👇 ow.ly/4QFi50OU81r Module 2 here👇 ow.ly/VLbq50OU81q
3.3M
HCC CONNECT powered by COR2ED
@hccconnectinfo
Jul 26, 2021
In this podcast, @SuPinChoo2 discusses in the field of #HCC the latest clinical data in 1L setting, stratification of patients & biomarkers from #ASCO21 & #WorldGI2021 + their clinical implications in #hepatocellularcarcinoma. Listen now ow.ly/L1Bm50FBuWz. #MedEd #oncology
00:00
HCC CONNECT powered by COR2ED
@hccconnectinfo
Nov 13, 2023
🔥Do you know when to switch to 2nd line treatment in advanced #HCC pts? ✅Switching to 2nd line is an assessment of toxicity and liver function Listen to 2 HCC experts discuss how long is too long in this educational podacst👇 ow.ly/UwaF50Q6i88 #MedEd #Liver
354K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Mar 31, 2023
Systemic treatments in #HCC are rapidly evolving! In this podcast experts Prof.James Harding and Prof. Sammy Saab discuss which patients with advanced HCC are not eligible for immunotherapy first-line and how to manage them Listen👇 ow.ly/po0C50NsEi0 #liverdisease #MedEd
215K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Oct 20, 2021
Here is our new podcast where @llovet_m & @StephenLChan1 discuss the use of VEGFR-TKIs monotherapy as first line treatment for unresectable or advanced HCC. Interested? See a short video to give you an idea & follow the link to listen the full podcast: ow.ly/jbHx50GuuuB
00:00
HCC CONNECT powered by COR2ED
@hccconnectinfo
Dec 21, 2023
🟡Ready for an immersive experience? 🟡 Join medical oncologist @TimonV in this interactive video & make key decisions throughout a patient journey with advanced #HCC. ❔When would you switch to 2nd line treatment?❔ Be part of the journey! ➡️ ow.ly/4ZyQ50QkVvl
00:00
504K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Jul 14, 2023
Looking to gain CME credit while improving your clinical practice? This #MedEd course on treatment options for pts with #HCC not eligible for or progressed on IO is; ▶️Accredited ▶️Free ▶️Expert led Access now: ow.ly/wOTJ50PbleH
00:00
1.5M
HCC CONNECT powered by COR2ED
@hccconnectinfo
Oct 12, 2022
New podcast from @PinterMatthias & Jeroen Dekervel discussing the clinical implications of new #HCC Phase 3 data presented at #ILCA22 and#ESMO22: - Role of immuno-oncology agents in 1L treatment - How to integrate them into clinical practice & guidelines ow.ly/EJvR50L7x4w
00:00
HCC CONNECT powered by COR2ED
@hccconnectinfo
Oct 1, 2021
Matthias Pinter, @hccconnectinfo member discusses the key data presented during the #ESMO21, #ILCA21 congresses on #hepatocellularcarcinoma #HCC See the link to listen to the podcast: ow.ly/Z9Ba50Gk1r7 Many thanks to @ILCAnews and @myESMO for such great topics! #MedEd
00:00
HCC CONNECT powered by COR2ED
@hccconnectinfo
Aug 18, 2025
Navigating advanced HCC: treatment strategies beyond immunotherapy (IO) Watch the video to explore treatment strategies for patients ineligible for IO or those with progression on IO Topics: - 1st line treatment options for patients ineligible for IO - Sequencing strategies,
00:00
420K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Nov 6, 2025
Post-IO progression in advanced HCC, two main approaches involving TKIs are available: Focus on 1st line TKIs (sorafenib or lenvatinib) or expand to all available 2nd line options  (sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab) Do you know when to
00:00
501K
HCC CONNECT powered by COR2ED
@hccconnectinfo
Mar 20, 2023
Listen to Prof Harding and Prof Saab in this podcast, discussing systemic treatment options for pts with advanced and intermediate #HCC, and what to do for advanced HCC pts who aren't eligible for IO 1st line. Listen here: ow.ly/I0T750Nl1RU #MedEd #liver
00:00
303K